Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 186 participants.
Also called NCT05347693
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 186 participants
- Sponsor
- Registry
-
NCT05347693 -
2021-003527-14
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Belgium, France, Italy, Netherlands, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05347693. Randomized; no masking; primary purpose treatment. Start 2022-03-24 (actual); primary completion 2024-12-10 (actual). Results posted on 2025-11-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
- Acronym
- CONTINUITY
- Condition
- Hyperkalaemia
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Sodium Zirconium Cyclosilicate (SZC)
- Intervention (Drug)
- Local standard of care
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct05347693- Content hash
e7b9a40c8e4d970edcb3e3b83921aa6fc06eba66161b80f0c42d432827c774ef